The University Technology Fund (UTF) – a co-investment by the Technology Innovation Agency and the SA SME Fund – has invested R13 million ($744,861) in two innovations to curb the spread of Covid-19.

One of the companies that benefits from the UTF is Hyrax Biosciences. The company is known for its contributions to HIV drug resistance testing. It has, however, utilised its Exatype platform to support the analysis of SARS-CoV-2. Exatype is a clinical-grade, disease-agnostic DNA analy...